Actos MDL - Consumer Drug Report
U.S. Judicial Panel to decide on Actos MDL

Actos® was released in July of 1999 and was intended for the purpose of increasing the body’s sensitivity to insulin in patients diagnosed with type II diabetes. It has grown in popularity over the years and brought in revenues of $4.3 billion in 2010 for Takeda. However, French drug regulators forced a recall of the Actos medication in that same year, contributing the recall to an increasing number of bladder cancer cases causes by Actos. In September of 2010 the Food and Drug Administration (FDA) began reviewing Actos risks and later required that Actos have updated warning labels.
Since then many cases were filed against the drug maker. Takeda Pharmaceuticals is aware of about 54 individual cases which have been filed in federal courts around the United States.
Currently, a panel of judges from the U.S. Judicial Panel on Multidistrict Litigation is preparing to make a decision regarding whether Actos bladder cancer lawsuits should be consolidated before one judge. In August, plaintiffs’ lawyers filed a motion to centralize Actos lawsuits into a multidistrict litigation (MDL). Takeda Pharmaceuticals agree with the motion, however, they do disagree regarding location for these pretrial proceedings. Oral arguments for a motion to centralize Actos bladder cancer lawsuits are scheduled for December 1, 2011at the Tomochichi United States Courthouse in Savannah, Georgia.
So far, dozens of Actos bladder cancer cases have been filed in various federal district courts. The first case was filed on July 29, 2011. Similar claims have been made amongst all of these cases that taking the type II diabetes drug has caused bladder cancer. Allegations were also made that Takeda Pharmaceuticals failed to properly warn about the side effects of taking Actos.
If an MDL is approved then all cases will go before the same judge. Any additional cases that are reviewed and filed would also be transferred to the same judge as well.

Tags: 
Categories: 

About the Contributor


Related Posts